MICL controls inflammation in rheumatoid arthritis

Pierre Redelinghuys; Lauren Whitehead; Andrea Augello; Rebecca A. Drummond; Jean-Michel  Levesque; Simon Vautier; Delyth M. Reid; Bernhard Kerscher; Julie A. Taylor; Peter A. Nigrovic; John Wright; Graeme I. Murray; Janet A. Willment; Lynne J. Hocking; Maria J. G. Fernandes; Cosimo De Bari; Iain B. McInnes; Gordon D. Brown

doi:10.1136/annrheumdis-2014-206644

MICL controls inflammation in rheumatoid arthritis

Pierre Redelinghuys, Lauren Whitehead, Andrea Augello, Rebecca A. Drummond, Jean-Michel Levesque, Simon Vautier, Delyth M. Reid, Bernhard Kerscher, Julie A. Taylor, Peter A. Nigrovic, John Wright, Graeme I. Murray, Janet A. Willment, Lynne J. Hocking, Maria J. G. Fernandes, Cosimo De Bari, Iain B. McInnes, Gordon D. Brown

Research output: Contribution to journal › Article › peer-review

39 Citations (Scopus)

12 Downloads (Pure)

Abstract

Background Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation.

Objective To determine the role of this CLR in inflammatory pathology using Clec12A−/− mice.

Methods Clec12A−/− mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis.

Results MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A−/− phenotype.

Conclusions MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.

Original language	English
Pages (from-to)	1386-1391
Number of pages	6
Journal	Annals of the Rheumatic Diseases
Volume	75
Issue number	7
Early online date	14 Aug 2015
DOIs	https://doi.org/10.1136/annrheumdis-2014-206644
Publication status	Published - Jul 2016

Bibliographical note

Acknowledgments
We thank G Milne, D MacCallum, S Hardison, G Wilson, C Wallace, S Hadebe and A Richmond for assistance; H. El-Gabalawy for tissues and the animal facility staff for the care of our animals. Flow cytometry was undertaken in the Iain Fraser Cytometry Centre, University of Aberdeen.

Funding:
GDB was funded by the Wellcome Trust and MRC (UK). AA and CDB are supported by the Arthritis Research UK Tissue Engineering Centre (grant 19429). This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk, and was funded by the Wellcome Trust (076113). MJGF was funded by The Arthritis Society and the Canadian Arthritis Network and J-ML by a scholarship from the Canadian Arthritis Network.

Access to Document

10.1136/annrheumdis-2014-206644Licence: CC BY

MICL controls inflammation in rheumatoid arthritis
This is an Open Access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 4.0) license, which permits others to distribute, remix, adapt and build upon this work, for commercial use, provided the original work is properly cited. See: http://creativecommons.org/licenses/by/4.0/
Final published version, 988 KBLicence: CC BY

Cosimo De Bari
Person: Clinical Academic

Iain Fraser Cytometry Centre
Andrea Holme (Manager), Linda Duncan (Senior Application Scientist), Ailsa Laird (Technician) & Kate Burgoyne (Technician)
Institute of Medical Sciences
Research Facilities: Facility

Cite this

Redelinghuys, P., Whitehead, L., Augello, A., Drummond, R. A., Levesque, J.-M., Vautier, S., Reid, D. M., Kerscher, B., Taylor, J. A., Nigrovic, P. A., Wright, J., Murray, G. I., Willment, J. A., Hocking, L. J., Fernandes, M. J. G., De Bari, C., McInnes, I. B., & Brown, G. D. (2016). MICL controls inflammation in rheumatoid arthritis. Annals of the Rheumatic Diseases, 75(7), 1386-1391. https://doi.org/10.1136/annrheumdis-2014-206644

Redelinghuys, P, Whitehead, L, Augello, A, Drummond, RA, Levesque, J-M, Vautier, S, Reid, DM, Kerscher, B, Taylor, JA, Nigrovic, PA, Wright, J, Murray, GI, Willment, JA, Hocking, LJ, Fernandes, MJG, De Bari, C, McInnes, IB & Brown, GD 2016, 'MICL controls inflammation in rheumatoid arthritis', Annals of the Rheumatic Diseases, vol. 75, no. 7, pp. 1386-1391. https://doi.org/10.1136/annrheumdis-2014-206644

@article{600f4ad1903b420493e0c36a0a6f00f3,

title = "MICL controls inflammation in rheumatoid arthritis",

abstract = "Background Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation.Objective To determine the role of this CLR in inflammatory pathology using Clec12A−/− mice.Methods Clec12A−/− mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis.Results MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A−/− phenotype.Conclusions MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.",

author = "Pierre Redelinghuys and Lauren Whitehead and Andrea Augello and Drummond, {Rebecca A.} and Jean-Michel Levesque and Simon Vautier and Reid, {Delyth M.} and Bernhard Kerscher and Taylor, {Julie A.} and Nigrovic, {Peter A.} and John Wright and Murray, {Graeme I.} and Willment, {Janet A.} and Hocking, {Lynne J.} and Fernandes, {Maria J. G.} and {De Bari}, Cosimo and McInnes, {Iain B.} and Brown, {Gordon D.}",

note = "Acknowledgments We thank G Milne, D MacCallum, S Hardison, G Wilson, C Wallace, S Hadebe and A Richmond for assistance; H. El-Gabalawy for tissues and the animal facility staff for the care of our animals. Flow cytometry was undertaken in the Iain Fraser Cytometry Centre, University of Aberdeen. Funding: GDB was funded by the Wellcome Trust and MRC (UK). AA and CDB are supported by the Arthritis Research UK Tissue Engineering Centre (grant 19429). This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk, and was funded by the Wellcome Trust (076113). MJGF was funded by The Arthritis Society and the Canadian Arthritis Network and J-ML by a scholarship from the Canadian Arthritis Network.",

year = "2016",

month = jul,

doi = "10.1136/annrheumdis-2014-206644",

language = "English",

volume = "75",

pages = "1386--1391",

journal = "Annals of the Rheumatic Diseases",

issn = "0003-4967",

publisher = "BMJ Publishing Group",

number = "7",

}

TY - JOUR

T1 - MICL controls inflammation in rheumatoid arthritis

AU - Redelinghuys, Pierre

AU - Whitehead, Lauren

AU - Augello, Andrea

AU - Drummond, Rebecca A.

AU - Levesque, Jean-Michel

AU - Vautier, Simon

AU - Reid, Delyth M.

AU - Kerscher, Bernhard

AU - Taylor, Julie A.

AU - Nigrovic, Peter A.

AU - Wright, John

AU - Murray, Graeme I.

AU - Willment, Janet A.

AU - Hocking, Lynne J.

AU - Fernandes, Maria J. G.

AU - De Bari, Cosimo

AU - McInnes, Iain B.

AU - Brown, Gordon D.

N1 - Acknowledgments We thank G Milne, D MacCallum, S Hardison, G Wilson, C Wallace, S Hadebe and A Richmond for assistance; H. El-Gabalawy for tissues and the animal facility staff for the care of our animals. Flow cytometry was undertaken in the Iain Fraser Cytometry Centre, University of Aberdeen. Funding: GDB was funded by the Wellcome Trust and MRC (UK). AA and CDB are supported by the Arthritis Research UK Tissue Engineering Centre (grant 19429). This study makes use of data generated by the Wellcome Trust Case Control Consortium. A full list of the investigators who contributed to the generation of the data is available from http://www.wtccc.org.uk, and was funded by the Wellcome Trust (076113). MJGF was funded by The Arthritis Society and the Canadian Arthritis Network and J-ML by a scholarship from the Canadian Arthritis Network.

PY - 2016/7

Y1 - 2016/7

N2 - Background Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation.Objective To determine the role of this CLR in inflammatory pathology using Clec12A−/− mice.Methods Clec12A−/− mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis.Results MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A−/− phenotype.Conclusions MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.

AB - Background Myeloid inhibitory C-type lectin-like receptor (MICL, Clec12A) is a C-type lectin receptor (CLR) expressed predominantly by myeloid cells. Previous studies have suggested that MICL is involved in controlling inflammation.Objective To determine the role of this CLR in inflammatory pathology using Clec12A−/− mice.Methods Clec12A−/− mice were generated commercially and primarily characterised using the collagen antibody-induced arthritis (CAIA) model. Mechanisms and progress of disease were characterised by clinical scoring, histology, flow cytometry, irradiation bone-marrow chimera generation, administration of blocking antibodies and in vivo imaging. Characterisation of MICL in patients with rheumatoid arthritis (RA) was determined by immunohistochemistry and single nucleotide polymorphism analysis. Anti-MICL antibodies were detected in patient serum by ELISA and dot-blot analysis.Results MICL-deficient animals did not present with pan-immune dysfunction, but exhibited markedly exacerbated inflammation during CAIA, owing to the inappropriate activation of myeloid cells. Polymorphisms of MICL were not associated with disease in patients with RA, but this CLR was the target of autoantibodies in a subset of patients with RA. In wild-type mice the administration of such antibodies recapitulated the Clec12A−/− phenotype.Conclusions MICL plays an essential role in regulating inflammation during arthritis and is an autoantigen in a subset of patients with RA. These data suggest an entirely new mechanism underlying RA pathogenesis, whereby the threshold of myeloid cell activation can be modulated by autoantibodies that bind to cell membrane-expressed inhibitory receptors.

U2 - 10.1136/annrheumdis-2014-206644

DO - 10.1136/annrheumdis-2014-206644

M3 - Article

SN - 0003-4967

VL - 75

SP - 1386

EP - 1391

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

IS - 7

ER -

MICL controls inflammation in rheumatoid arthritis

Abstract

Bibliographical note

Access to Document

Fingerprint

Profiles

Cosimo De Bari

Equipment

Iain Fraser Cytometry Centre

Cite this